Parmax Pharma raises ₹19.28 cr, hands control to 14 new investors
The raise is worth 113% of the company's ₹17 cr market cap. The new allottees will become majority owners.
— 2 earlier stories on Parmax Pharma Ltd. →What's new
- Board approved issuing 31.4 lakh shares and 21.5 lakh warrants at ₹36.50 each to raise ₹19.28 cr.
- The allottees, led by Dhiren and Sunil Shah, will become majority owners.
- The raise follows a 57% revenue decline and auditor-flagged governance red flags.
Why this matters
This isn't a routine capital raise. A ₹19.28 cr infusion into a company with a ₹17 cr market cap is a takeover in all but name. The new investors are taking control of a business in distress, betting the governance issues and collapsing revenue can be fixed with fresh capital and new ownership.
What we're watching
- Whether minority shareholders approve the issue at the July 2 EGM.
- The timeline for the new control group to execute a turnaround.
- Whether auditor governance concerns are resolved post-change of control.
The full read
Parmax Pharma is raising ₹19.28 crore through a preferential issue that will hand majority control to 14 new investors. That's the headline, but the context is what matters. The raise is worth 113% of the company's ₹17 crore market cap. The business is in distress, with a 57% revenue decline, widening losses, and auditors who have already flagged governance red flags. The new control group, led by Dhiren and Sunil Shah, is taking over a company worth less than the cash it's putting in. The issue price of ₹36.50 a share carries a premium over recent trading, but the authorized share capital has to be expanded from ₹6 crore to ₹10 crore just to fit the new stock. Shareholder approval at a July 2 EGM is the next gate.
Questions answered
- How large is this raise relative to Parmax Pharma's size?
- The ₹19.28 cr preferential issue is worth 113% of the company's ₹17 cr market capitalization. It will increase the authorized share capital from ₹6 cr to ₹10 cr to accommodate the new shares.
- Who is taking control of the company?
- 14 individuals led by Dhiren Chandulal Shah and Sunil Chinubhai Shah will become majority owners through the allotment of equity shares and convertible warrants at ₹36.50 each.
- Why is the company raising this money?
- The proceeds are for general corporate purposes. The raise comes as Parmax grapples with a 57% revenue decline and widening losses, with auditors having flagged governance concerns.
- What happens next?
- The preferential issue requires shareholder approval at an extraordinary general meeting scheduled for July 2. The board has already unanimously recommended the issue.
Story so far
All notes on PARMAX →- 8 Jun 2026 · 3:24 PM IST Parmax Pharma raises ₹19.28 cr, hands control to 14 new investors
- 5d ago Parmax Pharma turns to a preferential issue after a 57% revenue crash.
- 5d ago Parmax Pharma revenue halved, auditors flag MD's use of company funds